Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure [0.03%]
多中心真实世界评估CAR-T治疗失败后大B细胞淋巴瘤患者Post-CAR预后指数的研究
Mirko Farina,Elena Maiolo,Chiara Ghiggi et al.
Mirko Farina et al.
Most patients with large B-cell lymphoma (LBCL) progressing after CAR-T therapy experience poor survival and lack standardized treatment strategies. Prognostic tools are needed to guide decision-making at relapse. The Post-CAR Prognostic In...
Multicenter Study
Journal of hematology & oncology. 2026 Jan 8;19(1):4. DOI:10.1186/s13045-025-01771-6 2026
A subcellular spatial atlas illuminates the microenvironmental remodeling of perineural invasion in distal cholangiocarcinoma [0.03%]
远端胆管癌神经周围浸润微环境重塑的亚细胞空间图谱
Fansen Ji,Hao Chen,Huan Li et al.
Fansen Ji et al.
Distal cholangiocarcinoma (dCCA) arises from the distal bile duct and is anatomically embedded within the pancreatic head, adjacent to abundant autonomic nerve plexuses. This unique location renders dCCA particularly prone to perineural inv...
Clinical validation of UroCAD test for upper tract urothelial carcinoma detection: results from a prospective multi-center study [0.03%]
UroCAD检测上尿路尿路上皮癌的临床验证：一项前瞻性多中心研究结果
Guoliang Yang,Shuxiong Zeng,Wei He et al.
Guoliang Yang et al.
Background: Upper tract urothelial carcinoma (UTUC) poses diagnostic challenges due to its anatomical complexity and limited accessibility. Methods: ...
Multicenter Study
Journal of hematology & oncology. 2026 Jan 9;19(1):8. DOI:10.1186/s13045-025-01772-5 2026
Michael Conry,Irina Ostrovnaya,Yelena Kemel et al.
Michael Conry et al.
Background: DNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM). ...
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies [0.03%]
CD47阻滞引发的坏死性凋亡可补充BCL-2抑制驱动的淋巴肿瘤细胞凋亡
Stephen J F Chong,Rebecca Valentin,Jing Wang et al.
Stephen J F Chong et al.
Aberrant KIF26B expression promotes bladder cancer progression through driving NSUN2 nuclear localization [0.03%]
KIF26B表达异常通过促进NSUN2核定位来促进膀胱癌进展
Jia-Ming Wang,Hai-Yun Xie,Feng-Hao Zhang et al.
Jia-Ming Wang et al.
Abnormal expression of kinesins has been observed in several types of cancer. The present study provided the first evidence that KIF26B could induce RNA m5C modification in bladder cancer (BCa). Detailly, KIF26B interacted with NSUN2 and re...
Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia [0.03%]
成人复发/难治急性髓系白血病患者接受CLL1-CAR-T细胞治疗的最新数据更新
Xiaomei Zhang,Wenyi Lu,Wenjun Zhang et al.
Xiaomei Zhang et al.
CLL1-targeted chimeric antigen receptor T (CAR-T) cell therapy has shown clinically meaningful activity in relapsed/refractory acute myeloid leukemia (R/R AML). This updated phase I study enrolled 38 adults with R/R AML to evaluate the safe...
Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits [0.03%]
工程改造细菌以增强肿瘤治疗：从表面修饰到合成遗传线路
Yuanxiang Wang,Susu Xiao,Wei Yu et al.
Yuanxiang Wang et al.
Bacterial therapy represents a promising strategy for cancer treatment, in which tumor regression can be achieved through bacteria-mediated immunotherapy. The mechanisms involve disrupting cellular metabolism, inducing apoptosis, delivering...
Mitochondria at the intersections of RNA modifications and metabolism reprogramming implications in cell death, tumor microenvironment, and immunotherapy [0.03%]
线粒体在RNA修饰和代谢重编程的交叉路口：对细胞死亡、肿瘤微环境和免疫治疗的影响
Jiaxun Zhang,Haoxuan Zhang,Leifeng Chen et al.
Jiaxun Zhang et al.
Mitochondria, the powerhouse of the cell, orchestrate a plethora of critical functions, including energy production, metabolic regulation, programmed cell death, and signal transduction. Their pivotal role in the pathogenesis of numerous di...
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy [0.03%]
太平洋5研究：维持性度伐单抗用于不可切除的III期NSCLC患者同步或序贯放化疗无进展后的巩固治疗三期临床试验
Yi-Long Wu,Lin Wu,Nan Bi et al.
Yi-Long Wu et al.
Background: Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC). However, in clinical practice many pa...